Mangangot, Mark Caleb R.
HRN: 24-14-40 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/10/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/10/2025
01/16/2025
IV
50mg
Q12
PCAP C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes